E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Time for a prepublication culture in clinical research
TL;DR: This policy, known as the “Ingelfinger rule”, has had a major role in determining the ethos of publication in clinical research, and was revisited at least three times.
Journal ArticleDOI
Virtual care for improved global health.
TL;DR: The ability to provide health care almost anywhere in the world, inconceivable just years ago, is now possible; systems of care built around improved communications, bringing care closer to, if not directly to, the individual, and bolstering self-management.
Journal ArticleDOI
The genetics of health
Joseph H. Nadeau,Eric J. Topol +1 more
TL;DR: This work proposes testing specifically for modifier genes and protective alleles among at-risk individuals and studying the efficacy of therapeutics based on the genetics of health in patients genetically predisposed to disease.
Journal ArticleDOI
Redefining medical treatment in the management of unstable angina.
Eugene Braunwald,Robert M. Califf,Christopher P. Cannon,Keith A.A. Fox,Valentin Fuster,W. Brian Gibler,RA Harrington,Spencer B. King,Neil S. Kleiman,Pierre Théroux,Eric J. Topol,Frans Van de Werf,Harvey D. White,James T. Willerson +13 more
TL;DR: Consideration should be given to measuring serum levels of a cardiac troponin (either T or I) and using intravenous GP IIb-IIIa inhibitors and low-molecular-weight heparin in the standard management of patients with unstable angina.
Journal ArticleDOI
Common variations in platelet glycoproteins: pharmacogenomic implications.
Martin J. Quinn,Eric J. Topol +1 more
TL;DR: The current knowledge of the influence of genetic make-up on antiplatelet therapy is discussed.